Looking at the "Insights into anthracycline-induced cardiotoxicity and treatment perspectives" session which Ngo is co chairing, I get a fear of 'opportunities flying past' - unless one of them is from our ours!
Lots of posters too - I only got a 3rd way down the list in my rush browsing.
Maybe we are not ready yet !
Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after doxorubicin treatment
Cardiac troponin autoantibodies in breast cancer patients receiving adjuvant cardiotoxic chemotherapy: the PRADA study
Cardioprotective effects of the flavonoid quercetin against doxorubicin-Induced cardiotoxicity in H9c2 cardiomyoblasts
Exploring the cardioprotective efficacy of roflumilast as potential cAMP regulator against experimental epirubicin-induced myocardial injury: insights into oxidative stress and apoptosis
Anthracycline exposure alters the response to future cardiac stress response driven by FOXK1
Epigenetic repression by SAHA leads to cardio-protection in anthracycline-induced long-term cardiotoxicity
Unveiling doxorubicin-induced cardiotoxicity: into the heart with single-cell resolution
In vitro platform to model anthracycline-induced cardiotoxicity and evaluate cardioprotective agents in human -induced pluripotent stem cells-derived cardiomyocytes
GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidencesPresenter
Melt electrowritten 3D human cardiac engineered tissues reproduce the enhanced sensitivity of fibrotic patients to doxorubicin
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
!
(20min delay)